Curiox BioSystems Co

Curiox BioSystems Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Curiox BioSystems Co (445680.KQ) as of Oct 27, 2026 is 123.08 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 83.42 % — a change of 47.54% (higher).

FCF Conversion

123.08 %

YoY

47.54%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Curiox BioSystems Co is 2024 123.08 % . FCF Conversion Rate (FCF/EBITDA) of Curiox BioSystems Co was 2023 83.42 % . It decreases by 47.54% higher compared to the previous year.

The Curiox BioSystems Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2021
37.09 KRW
Jan 1, 2022
93.34 KRW
Jan 1, 2023
83.42 KRW
Jan 1, 2024
123.08 KRW
The Curiox BioSystems Co FCF Conversion history
YEARFCF ConversionYoY
123.08 %+47.54%
83.42 %-10.63%
93.34 %+151.65%
37.09 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Curiox BioSystems Co Stock analysis

What does Curiox BioSystems Co do? Curiox BioSystems Co Ltd generates revenue through the manufacture and sale of automation equipment and consumables for cell analysis processes. The company offers cell pretreatment automation devices, washing machines, and plates, alongside high-capacity adapters, strip spacers, and buffer exchanger products. These products are sold to customers in the Life Sciences Tools & Services industry, primarily within the Korean market. The firm's focus on automation solutions for cell analysis drives its product portfolio and customer base. The company's product lines include cell pretreatment automation devices, washing machines, plates, high-capacity adapters, strip spacers, and buffer exchanger products. These items are designed for use in cell analysis processes, targeting clients who require efficient and precise laboratory equipment. The sales of these specialized tools form the core of Curiox BioSystems' revenue streams. Curiox BioSystems operates within the Life Sciences Tools & Services industry, focusing on providing automation solutions for cell analysis. Its products are manufactured and sold directly to end-users in the life sciences sector, including research institutions and laboratories. The company's revenue is derived from the direct sale of its equipment and consumables without intermediaries. Curiox BioSystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curiox BioSystems Co stock

FCF Conversion Rate (FCF/EBITDA) of Curiox BioSystems Co is 123.08 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Curiox BioSystems Co changed from 83.42 % to 123.08 %, representing a 47.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Curiox BioSystems Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Curiox BioSystems Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Curiox BioSystems Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Curiox BioSystems Co